Knott David M Jr Takes $1.27 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Knott David M Jr acquired a new position in Regeneron Pharmaceuticals, buying 2,000 shares valued at approximately $1.27 million, which makes this stock his 26th largest holding.
• Regeneron Pharmaceuticals reported $12.89 earnings per share for the last quarter, significantly exceeding analysts' expectations of $8.43, indicating strong financial performance.
• The company announced a quarterly dividend of $0.88 per share with an annualized yield of 0.6%, reflecting its stable dividend policy amidst its growth forecasts.

Knott David M Jr purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 2,000 shares of the biopharmaceutical company's stock, valued at approximately $1,268,000. Regeneron Pharmaceuticals accounts for about 0.6% of Knott David M Jr's holdings, making the stock its 26th largest holding.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Pinney & Scofield Inc. bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 31 shares during the period. Costello Asset Management INC bought a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $27,000. Tompkins Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $32,000. Finally, Curat Global LLC bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth $32,000. 83.31% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on REGN. Canaccord Genuity Group reaffirmed a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. BMO Capital Markets boosted their price objective on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a research note on Monday, August 4th. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Guggenheim upped their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Finally, Morgan Stanley restated an "overweight" rating and set a $761.00 target price (up from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $841.30.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $563.00 on Monday. The company has a market capitalization of $59.67 billion, a PE ratio of 14.19, a price-to-earnings-growth ratio of 1.91 and a beta of 0.33. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company's fifty day moving average price is $536.80 and its 200 day moving average price is $598.52. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. The company had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.56 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.